Advanced Or Metastatic Non Small Cell Lung Cancer clinical trials

Explore recruiting advanced or metastatic non small cell lung cancer clinical trials.

Recruiting advanced or metastatic non small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Or Metastatic Non Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer

Spain, Romania

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 2 Study of Zelenectide Pevedotin in Participants with Previously-Treated NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

Italy, Spain, France, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH OR WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01)

Spain, Poland, France, Belgium, Italy, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC)

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY

Romania, Netherlands, Ireland, Italy, France, Germany +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Belgium, France, Spain, Germany, Austria, Italy +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Advanced Or Metastatic Non Small Cell Lung Cancer trials by city

Advanced Or Metastatic Non Small Cell Lung Cancer in Toronto Advanced Or Metastatic Non Small Cell Lung Cancer in Vancouver Advanced Or Metastatic Non Small Cell Lung Cancer in Montreal Advanced Or Metastatic Non Small Cell Lung Cancer in Calgary Advanced Or Metastatic Non Small Cell Lung Cancer in Edmonton Advanced Or Metastatic Non Small Cell Lung Cancer in Ottawa Advanced Or Metastatic Non Small Cell Lung Cancer in Winnipeg Advanced Or Metastatic Non Small Cell Lung Cancer in Quebec City Advanced Or Metastatic Non Small Cell Lung Cancer in Hamilton Advanced Or Metastatic Non Small Cell Lung Cancer in Kitchener Advanced Or Metastatic Non Small Cell Lung Cancer in London Advanced Or Metastatic Non Small Cell Lung Cancer in Halifax Advanced Or Metastatic Non Small Cell Lung Cancer in New York Advanced Or Metastatic Non Small Cell Lung Cancer in Los Angeles Advanced Or Metastatic Non Small Cell Lung Cancer in Chicago Advanced Or Metastatic Non Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease